Liisi Leis

Life-sustaining artificial kidney treatment or haemodialysis (HD) is needed for end-stage renal disease and critical care patients. High quality HD must ensure effective and personalized blood purification from harmful uremic toxins (UT), among inflammation-cardiovascular disease related middle size (MM)-UT. This, urged by a need for HD surveillance in crisis (coronavirus, war, energy), has created a demand for on-line, bloodless, and non-infectious tools for UT removal monitoring. Optical monitoring can provide a feasible tool for this. However, to date no reliable monitoring technology of MM-UTs is available. This project aims to fill this knowledge gap. Optical spectral signature identification combined with chromatographic and biochemical analyses to reveal the main optical MM markers in biofluids, selection of best signal processing algorithms, and a proof-of-concept in-vivo clinical study is planned to develop a novel optical technology for on-line MM-UT removal monitoring in HD.

Around 13% of the adult population suffers some form of kidney damage, and the death rate of complications related to chronic kidney disease (CKD) is very high. The primary cause of death in CKD patients is cardiovascular disease. Vascular calcification (VC), one of the cardiovascular complications, is prevailing in CKD. One of the causes of VC in CKD is the disbalance between VC inhibitors and inducers due to failed kidney function. During the dialysis therapy for end-stage renal disease (ESRD) patients, inducers and also inhibitors are removed from the patients’ blood. This project (VasCalDi) aims to develop unique optical methods to estimate VC and monitor VC inhibitors removal during dialysis in patients with ESRD. The project's goal is to make the work of hospitals and physicians more efficient and improve the life quality and survival of ESRD patients by monitoring disturbances in VC inhibitor balance and vasculature allowing timely interventions.